NeuroPace IncNPCE
What NeuroPace Inc does.
We are a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Our novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. By continuously monitoring and analyzing the brain’s electrical activity, recognizing patient-specific abnormal electrical patterns, and responding in real time with imperceptible electrical pulses to prevent seizures, our RNS System is programmed by clinicians to deliver the precise amount of therapy when and where it is needed and provides exceptional clinical outcomes with approximately three minutes of stimulation on average per day. Our RNS System is also the only commercially available device that records continuous brain activity data and allows clinicians to monitor patients not only in person, but also remotely, providing them the data they need to make more informed treatment decisions, thus optimizing patient care. We believe the therapeutic advantages of our RNS System, combined with the insights obtained from our extensive brain data set, offer a significant leap forward in epilepsy treatment. As of December 31, 2025, over 8,000 patients have received our RNS System. We believe our compelling body of long-term clinical data, demonstrating continuous improvement in outcomes over time, will support the continued adoption of our RNS System among the approximately 575,000 adults in the United States with drug-resistant focal epilepsy. We continue seeking indication expansion to, over time, cover the entire approximately 1.2 million drug-resistant epilepsy patients in the United States and may additionally seek to expand our operations to reach the approximately 16.5 million drug-resistant epilepsy patients globally.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.1M | $45.2M | $45.5M | $65.4M | $79.9M | $100.0M |
| Net income | -$24.3M | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| Free cash flow | -$21.7M | -$25.0M | -$37.5M | -$19.9M | -$18.3M | -$11.3M |
More on NPCE.
- NeuroPace Inc summary
- NeuroPace Inc financial statements
- NeuroPace Inc key metrics
- NeuroPace Inc health scores and style box
- NeuroPace Inc earnings
- NeuroPace Inc dividends
- NeuroPace Inc valuation
- NeuroPace Inc ownership and insiders
- NeuroPace Inc peers
Figures from NeuroPace Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.